ArticleP & T : a peer-reviewed journal for formulary management2017
Hepatitis C in a New Era: A Review of Current Therapies.
Article in P & T : a peer-reviewed journal for formulary management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era: A Meta-Analysis.American journal of preventive medicine · 2023Pooled it
- Hepatitis C virus infection is associated with high risk of breast cancer: a pooled analysis of 68,014 participants.Frontiers in oncology · 2023Pooled it
- Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.BMC infectious diseases · 2020Trial
- Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery.Chemical biology & drug design · 2026Review
- Hepatitis C-Everything a Primary Care Physician Needs to Know About Diagnosis, Management, and Follow-Up.Journal of clinical medicine · 2025Review
- Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada.Canadian liver journal · 2025Article
- Host immune players and their response to Hepatitis C therapies.PLOS global public health · 2024Article
- Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Article
- Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.Archives of virology · 2022Review
- Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management.Journal of multidisciplinary healthcare · 2022Review
- Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis.Respiratory medicine · 2021Article
- Two years into COVID-19 - Lessons in SARS-CoV-2 and a perspective from papers in FEBS Letters.FEBS letters · 2021Review
- Hospital Admission Trends Due to Viral Infections Characterised by Skin and Mucous Membrane Lesions in the Past Two Decades in England and Wales: An Ecological Study.International journal of environmental research and public health · 2021Article
- Monitoring reversion of hepatitis C virus-induced cellular alterations by direct-acting antivirals using cryo soft X-ray tomography and infrared microscopy.Acta crystallographica. Section D, Structural biology · 2021Article
- An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs.BMC complementary medicine and therapies · 2021Article
- Drug combination therapy for emerging viral diseases.Drug discovery today · 2021Review
- Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly.Journal of medicinal chemistry · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors summarize newly available HCV treatment regimens, their indications, studies supporting their efficacy and safety, and special considerations for each regimen, such as patient comorbidities.
Identifiers
28479841PMC5398625What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.